ReviewAmerican journal of cancer research2026
Research progress on the intrinsic link between the occurrence and progression of malignant tumors, chronic kidney disease and drug safety.
Review in American journal of cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is a close intrinsic link between the occurrence, development, and medication use of malignant tumors and chronic kidney disease (CKD). Firstly, CKD provides conditions for the occurrence and progression of malignant tumors, such as the accumulation of uremic toxins, inflammatory responses, immune dysfunction, and metabolic disorders. Simultaneously, malignant tumors can damage the kidneys through paraneoplastic effect, direct tumor invasion, or compression. In addition, the treatment of malignant tumors can also trigger or worsen CKD. Therefore, improving early cancer screening for CKD patients and exploring the safety of medications used in CKD patients with concurrent cancer are of significant clinical importance. Based on this, this article reviews recent research on the interaction between CKD and malignant tumors and the safety of medications used, aiming to provide important theoretical basis for improving the diagnosis and treatment of CKD with concurrent cancer and improving the prognosis of these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.